Abstract
During embryogenesis there is an exquisite orchestration of cellular division, movement, differentiation, and death. Cell death is one of the most important aspects of organization of the developing embryo, as alteration in timing, level, or pattern of cell death can lead to developmental anomalies. Cell death shapes the embryo and defines the eventual functions of the organs. Cells die using different paths; understanding which path a dying cell takes helps us define the signals that regulate the fate of the cell. Our understanding of cell death in development stems from a number of observations indicating genetic regulation of the death process. With todays increased knowledge of the pathways of cell death and the identification of the genes whose products regulate the pathways we know that, although elimination of some of these gene products has no developmental phenotype, alteration of several others has profound effects. In this review we discuss the types and distributions of cell death seen in developing mammalian embryos as well as the gene products that may regulate the process.
Keywords: Programmed Cell Death, Embryonic Development, Apoptosis, Necrosis, Autophagy
Current Pharmaceutical Design
Title: Cell Death in Mammalian Development
Volume: 14 Issue: 2
Author(s): Z. Zakeri, C. Penaloza, S. Orlanski, Y. Ye, T. Entezari-Zaher and M. Javdan
Affiliation:
Keywords: Programmed Cell Death, Embryonic Development, Apoptosis, Necrosis, Autophagy
Abstract: During embryogenesis there is an exquisite orchestration of cellular division, movement, differentiation, and death. Cell death is one of the most important aspects of organization of the developing embryo, as alteration in timing, level, or pattern of cell death can lead to developmental anomalies. Cell death shapes the embryo and defines the eventual functions of the organs. Cells die using different paths; understanding which path a dying cell takes helps us define the signals that regulate the fate of the cell. Our understanding of cell death in development stems from a number of observations indicating genetic regulation of the death process. With todays increased knowledge of the pathways of cell death and the identification of the genes whose products regulate the pathways we know that, although elimination of some of these gene products has no developmental phenotype, alteration of several others has profound effects. In this review we discuss the types and distributions of cell death seen in developing mammalian embryos as well as the gene products that may regulate the process.
Export Options
About this article
Cite this article as:
Zakeri Z., Penaloza C., Orlanski S., Ye Y., Entezari-Zaher T. and Javdan M., Cell Death in Mammalian Development, Current Pharmaceutical Design 2008; 14 (2) . https://dx.doi.org/10.2174/138161208783378789
DOI https://dx.doi.org/10.2174/138161208783378789 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applications of Gene Transfer to Targeted Radiotherapy
Current Pharmaceutical Design Extracellular Citrate in Health and Disease
Current Molecular Medicine Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Genotoxicity in Alzheimers Disease: Role of Amyloid
Current Alzheimer Research Histone Deacetylase Inhibitors in Tumor Immunotherapy
Current Medicinal Chemistry Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Sulfur-based Mechanistic Probes for Enzyme-catalyzed Reactions
Current Medicinal Chemistry The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
Current Pharmaceutical Design In Vitro and In Vivo Models of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy
Current Medicinal Chemistry Organosulphur Compounds Induce Apoptosis and Cell Cycle Arrest in Cervical Cancer Cells via Downregulation of HPV E6 and E7 Oncogenes
Anti-Cancer Agents in Medicinal Chemistry Current Management of Neonatal Soft-tissue Sarcomas and Benign Tumors with Local Aggressiveness
Current Pediatric Reviews Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Molecular Basis for the Neuroprotective Properties of FKBP-Binding Immunophilin Ligands
Current Medicinal Chemistry - Central Nervous System Agents Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design